.Pharmacolibrary.Drugs.ATC.R.R03AL03 .Pharmacolibrary.Drugs.ATC.R.R03AL03| name: | VilanterolAndUmeclidiniumBromide |
| ATC code: | R03AL03 | route: | inhalation |
| n-compartments | 2 |
Vilanterol and umeclidinium bromide is a fixed-dose combination of a long-acting beta2-adrenergic agonist (vilanterol) and a long-acting muscarinic antagonist (umeclidinium). It is approved and used as a maintenance treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).
Pharmacokinetic parameters are reported for healthy adult subjects following inhaled administration of the fixed dose combination.
Yang, S, et al., & Peachey, G (2021). Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). Clinical pharmacokinetics 60(7) 887–896. DOI:10.1007/s40262-021-00988-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33598874
Mehta, R, et al., & Lipson, DA (2020). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Clinical pharmacokinetics 59(1) 67–79. DOI:10.1007/s40262-019-00794-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/31321713